Expanding from its personalized cancer immunotherapy area of expertise, Europe’s largest private biotech BioNTech AG has signed a collaboration with Pfizer Inc. to develop messenger RNA (mRNA)-based vaccines for the prevention of influenza.
Interview: BioNTech And Pfizer Explore mRNA Flu Vaccines In $120m+ Deal
The German biotech's CBO and CCO Sean Marett tells Scrip that the Pfizer pact represents the first time BioNTech has moved into infectious disease in humans and could lead to higher potency flu vaccines that could be made more rapidly and cheaply.
More from Anti-infective
More from Therapy Areas
• By
The pact could be worth more than $2.6bn and adds to growing big pharma investment in the technology.
• By
Following the near-total dominance of IgG antibodies, the UK group is backing the potential of IgA and IgE-based therapies to transform cancer treatment with the purchase of US-headquartered TigaTx.
• By
By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.